Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Coya Therapeutics is entering into a phase 2b study for its ALS, and the biotech’s CEO believes it’s on the cusp of a game changer.

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...

Its lead product is NeuroNata-R (lenzumestrocel), the world’s first stem cell-based therapy for amyotrophic lateral sclerosis (ALS). NeuroNata-R was approved as an orphan drug for the treatment ...

Trouble sleeping is common in other neurodegenerative diseases, but past research has only suggested that it occurs in patients with amyotrophic lateral sclerosis. Now, a new study has not only ...

targeting calpain-2 for people living with amyotrophic lateral sclerosis (ALS). With the clinical hold lifted, Amylyx is now working to open U.S. sites for screening, enrollment, and dosing.

Lifearc has announced a collaboration with Neuropeutics Inc. to develop a new small molecule for the treatment of motor neuron disease (MND), or amyotrophic lateral sclerosis (ALS). Neuropeutics and ...

Formerly known as Lou Gehrig’s disease, amyotrophic lateral sclerosis is now commonly referred ... for a couple of months ...

For the primary analysis, 186 participants who were randomized to receive DNL343 treatment were compared to 139 participants randomized to receive placebo in this regimen (n=63) or shared from a ...

(MENAFN- EIN Presswire) What contributions are AB Science, Alector, GSK, and others making to the Amyotrophic Lateral Sclerosis treatment market? LAS VEGAS , NV, UNITED STATES, December 16 ...